These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15831855)

  • 1. Pfizer is asked to suspend sales of painkiller.
    Lenzer J
    BMJ; 2005 Apr; 330(7496):862. PubMed ID: 15831855
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA ponders future of NSAIDs: Pfizer reluctantly withdraws Bextra.
    Young D
    Am J Health Syst Pharm; 2005 May; 62(10):997, 1000. PubMed ID: 15901579
    [No Abstract]   [Full Text] [Related]  

  • 3. New COX-2 arthritis drug receives FDA approval.
    J Gend Specif Med; 2002; 5(2):6. PubMed ID: 11974679
    [No Abstract]   [Full Text] [Related]  

  • 4. COX-2 inhibitors--lessons in drug safety.
    Psaty BM; Furberg CD
    N Engl J Med; 2005 Mar; 352(11):1133-5. PubMed ID: 15713946
    [No Abstract]   [Full Text] [Related]  

  • 5. Raising the safety bar--the FDA's coxib meeting.
    Okie S
    N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221
    [No Abstract]   [Full Text] [Related]  

  • 6. Bitter pills for drug companies.
    Newman M
    BMJ; 2010 Sep; 341():c5095. PubMed ID: 20851842
    [No Abstract]   [Full Text] [Related]  

  • 7. Coxibs and cardiovascular disease.
    Fitzgerald GA
    N Engl J Med; 2004 Oct; 351(17):1709-11. PubMed ID: 15470192
    [No Abstract]   [Full Text] [Related]  

  • 8. What ails the FDA?
    Okie S
    N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
    [No Abstract]   [Full Text] [Related]  

  • 9. Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.
    Epstein RA
    Yale J Health Policy Law Ethics; 2005; 5(2):741-70. PubMed ID: 16052898
    [No Abstract]   [Full Text] [Related]  

  • 10. Don't blame it all on the bogey.
    Day M
    BMJ; 2007 Jun; 334(7606):1250-1. PubMed ID: 17569929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valdecoxib withdrawal leaves pain relief treatment gap.
    Lang L
    Gastroenterology; 2005 Jun; 128(7):1769-70. PubMed ID: 15940608
    [No Abstract]   [Full Text] [Related]  

  • 12. Over-the-counter sales of statins and other drugs for asymptomatic conditions.
    Tinetti ME
    N Engl J Med; 2008 Jun; 358(25):2728-32. PubMed ID: 18565867
    [No Abstract]   [Full Text] [Related]  

  • 13. New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra).
    Cotter J; Wooltorton E
    CMAJ; 2005 May; 172(10):1299. PubMed ID: 15833921
    [No Abstract]   [Full Text] [Related]  

  • 14. Caveat doctor.
    McCarthy M
    Lancet; 1999 Aug; 354(9177):446. PubMed ID: 10465167
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA to steer nanotech.
    Fox JL
    Nat Biotechnol; 2008 Oct; 26(10):1060. PubMed ID: 18846060
    [No Abstract]   [Full Text] [Related]  

  • 16. PDUFA V goes back to basics.
    Mullard A
    Nat Rev Drug Discov; 2012 Aug; 11(8):586-8. PubMed ID: 22850772
    [No Abstract]   [Full Text] [Related]  

  • 17. US lawmakers tackle safety reforms at the FDA.
    Zwillich T
    Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug safety special: the safety catch.
    Wadman M
    Nature; 2005 Mar; 434(7033):554-6. PubMed ID: 15800591
    [No Abstract]   [Full Text] [Related]  

  • 19. Trouble at the office.
    Allison M
    Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
    [No Abstract]   [Full Text] [Related]  

  • 20. Genta sued over NDA withdrawal.
    Mack GS
    Nat Biotechnol; 2004 Jul; 22(7):788-9. PubMed ID: 15229523
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.